Brief: Arvinas And Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival For Patients With Esr1-Mutant, Er+/Her2- Advanced Breast Cancer

Arvinas

31/05/2025 13:19

May 31 (Reuters) - Arvinas Inc ARVN.O:

ARVINAS AND PFIZER'S VEPDEGESTRANT SIGNIFICANTLY IMPROVES PROGRESSION-FREE SURVIVAL FOR PATIENTS WITH ESR1-MUTANT, ER+/HER2- ADVANCED BREAST CANCER

ARVINAS INC - VEPDEGESTRANT WELL TOLERATED WITH LOW GI ADVERSE EVENTS

ARVINAS INC - VEPDEGESTRANT FIRST PROTAC TO SHOW BENEFIT IN BREAST CANCER

ARVINAS INC - NDA FOR VEPDEGESTRANT TO BE SUBMITTED TO FDA IN SECOND HALF OF 2025

Source text: ID:nGNX5QqFpz

Further company coverage: ARVN.O

 ((Reuters.Briefs@thomsonreuters.com;))